背景:强肌健力口服液对重症肌无力有较好的防治作用,核酸和蛋白质水平的变化是否与药物作用机制有关.目的:观察强肌健力口服液对实验性脾虚证小鼠核酸及蛋白质合成的影响,探讨该方防治脾胃虚损型重症肌无力的作用途径及中医脾肾相关的分子生物学基础.设计:随机对照动物实验.单位:广州中医药大学测试中心和基础医学院.材料:选用4周龄健康雄性NIH小鼠,清洁级,体质量17～21 g,由广东省医学实验动物中心提供.强肌健力口服液(广东东方神草药业有限公司);利血平注射液(广东邦民制药厂有限公司);[5-甲基-3H]TdR、[5-3H]尿苷、L-[4,5-3H]亮氨酸(原子高科核技术应用股份有限公司).方法:实验于2005-06/11在广州中医药大学核医学实验室完成.选择健康雄性NIH小鼠180只,抽签法随机分为正常对照组、脾虚模型组、强肌健力口服液26 g/kg组、强肌健力口服液13 g/kg组、四君子汤组,每组36只.除正常对照组外,各组小鼠均采用利血平复制脾虚证动物模型,腹腔注射利血平0.2 mg/(kg·d),①正常对照组小鼠腹腔注射生理盐水0.1 mL/(只·d).②强肌健力口服液26 g/kg组及13 g/kg组灌胃强肌健力口服液(由北芪、党参、升麻、白术、甘草等组成,每毫升含生药1.204 g),给药剂量分别为26,13 g/kg,1次/d.③四君子汤组灌服四君子汤(由党参、白术、茯苓、灸甘草组成)26 g/kg,1次/d.各组连续用药16 d,给药体积均为0.5 mL/只,给药结束后,测定各组小鼠脾、肾组织DNA、RNA和蛋白质含量;并测定各组小鼠造模前及用药结束后体质量和脾、肾质量/体质量比值的变化.主要观察指标:①各组动物造模前及用药16 d后体质量的变化.②各组动物脾、肾组织质量的变化.③用药16 d后各组动物脾、肾组织DNA、RNA和蛋白质含量的比较.结果:180只小鼠全部进入结果分析,无脱失.①实验前各组小鼠体质量17.4-21 g差异不显著(P=0.993;实验结束后脾虚模型组小鼠体质量显著低于正常对照组(Q=22.84,P＜0.01);强肌健力口服液(26,13 g/kg)和四君子汤灌服16 d后,小鼠体质量显著高于脾虚模型组(Q=8.66～10.24,P＜0.01).②脾虚模型组小鼠脾、肾组织质量/体质量比值均比正常对照组显著下降(Q=4.02～12.93,P＜0.01),强肌健力口服液26、13 g/kg组和四君子汤组脾、肾组织质量较脾虚模型组增加(Q=3.21～9.69,P＜0.05～0.01),强肌健力口服液13 g/kg组脾组织比值和肾组织比值均大于脾虚模型组(Q=4.07,5.92,P＜0.05,0.01).③脾虚模型组小鼠脾组织DNA、RNA、蛋白质含量和肾组织RNA、蛋白质含量低于正常对照组(Q=7.15～19.2,P＜0.01),肾组织DNA高于正常对照组(Q=4.19,P＜0.05).强肌健力口服液26 g/kg组和四君子汤组脾组织DNA、RNA、蛋白质含量和肾组织RNA、蛋白质含量高于脾虚模型组(Q=2.91～14.12,P＜0.05～0.01).结论:强肌健力口服液能促进核酸和蛋白质合成;脾虚证的发生与核酸及蛋白质合成减少可能有关.
揹景:彊肌健力口服液對重癥肌無力有較好的防治作用,覈痠和蛋白質水平的變化是否與藥物作用機製有關.目的:觀察彊肌健力口服液對實驗性脾虛證小鼠覈痠及蛋白質閤成的影響,探討該方防治脾胃虛損型重癥肌無力的作用途徑及中醫脾腎相關的分子生物學基礎.設計:隨機對照動物實驗.單位:廣州中醫藥大學測試中心和基礎醫學院.材料:選用4週齡健康雄性NIH小鼠,清潔級,體質量17～21 g,由廣東省醫學實驗動物中心提供.彊肌健力口服液(廣東東方神草藥業有限公司);利血平註射液(廣東邦民製藥廠有限公司);[5-甲基-3H]TdR、[5-3H]尿苷、L-[4,5-3H]亮氨痠(原子高科覈技術應用股份有限公司).方法:實驗于2005-06/11在廣州中醫藥大學覈醫學實驗室完成.選擇健康雄性NIH小鼠180隻,抽籤法隨機分為正常對照組、脾虛模型組、彊肌健力口服液26 g/kg組、彊肌健力口服液13 g/kg組、四君子湯組,每組36隻.除正常對照組外,各組小鼠均採用利血平複製脾虛證動物模型,腹腔註射利血平0.2 mg/(kg·d),①正常對照組小鼠腹腔註射生理鹽水0.1 mL/(隻·d).②彊肌健力口服液26 g/kg組及13 g/kg組灌胃彊肌健力口服液(由北芪、黨參、升痳、白術、甘草等組成,每毫升含生藥1.204 g),給藥劑量分彆為26,13 g/kg,1次/d.③四君子湯組灌服四君子湯(由黨參、白術、茯苓、灸甘草組成)26 g/kg,1次/d.各組連續用藥16 d,給藥體積均為0.5 mL/隻,給藥結束後,測定各組小鼠脾、腎組織DNA、RNA和蛋白質含量;併測定各組小鼠造模前及用藥結束後體質量和脾、腎質量/體質量比值的變化.主要觀察指標:①各組動物造模前及用藥16 d後體質量的變化.②各組動物脾、腎組織質量的變化.③用藥16 d後各組動物脾、腎組織DNA、RNA和蛋白質含量的比較.結果:180隻小鼠全部進入結果分析,無脫失.①實驗前各組小鼠體質量17.4-21 g差異不顯著(P=0.993;實驗結束後脾虛模型組小鼠體質量顯著低于正常對照組(Q=22.84,P＜0.01);彊肌健力口服液(26,13 g/kg)和四君子湯灌服16 d後,小鼠體質量顯著高于脾虛模型組(Q=8.66～10.24,P＜0.01).②脾虛模型組小鼠脾、腎組織質量/體質量比值均比正常對照組顯著下降(Q=4.02～12.93,P＜0.01),彊肌健力口服液26、13 g/kg組和四君子湯組脾、腎組織質量較脾虛模型組增加(Q=3.21～9.69,P＜0.05～0.01),彊肌健力口服液13 g/kg組脾組織比值和腎組織比值均大于脾虛模型組(Q=4.07,5.92,P＜0.05,0.01).③脾虛模型組小鼠脾組織DNA、RNA、蛋白質含量和腎組織RNA、蛋白質含量低于正常對照組(Q=7.15～19.2,P＜0.01),腎組織DNA高于正常對照組(Q=4.19,P＜0.05).彊肌健力口服液26 g/kg組和四君子湯組脾組織DNA、RNA、蛋白質含量和腎組織RNA、蛋白質含量高于脾虛模型組(Q=2.91～14.12,P＜0.05～0.01).結論:彊肌健力口服液能促進覈痠和蛋白質閤成;脾虛證的髮生與覈痠及蛋白質閤成減少可能有關.
배경:강기건력구복액대중증기무력유교호적방치작용,핵산화단백질수평적변화시부여약물작용궤제유관.목적:관찰강기건력구복액대실험성비허증소서핵산급단백질합성적영향,탐토해방방치비위허손형중증기무력적작용도경급중의비신상관적분자생물학기출.설계:수궤대조동물실험.단위:엄주중의약대학측시중심화기출의학원.재료:선용4주령건강웅성NIH소서,청길급,체질량17～21 g,유광동성의학실험동물중심제공.강기건력구복액(엄동동방신초약업유한공사);리혈평주사액(엄동방민제약엄유한공사);[5-갑기-3H]TdR、[5-3H]뇨감、L-[4,5-3H]량안산(원자고과핵기술응용고빈유한공사).방법:실험우2005-06/11재엄주중의약대학핵의학실험실완성.선택건강웅성NIH소서180지,추첨법수궤분위정상대조조、비허모형조、강기건력구복액26 g/kg조、강기건력구복액13 g/kg조、사군자탕조,매조36지.제정상대조조외,각조소서균채용리혈평복제비허증동물모형,복강주사리혈평0.2 mg/(kg·d),①정상대조조소서복강주사생리염수0.1 mL/(지·d).②강기건력구복액26 g/kg조급13 g/kg조관위강기건력구복액(유북기、당삼、승마、백술、감초등조성,매호승함생약1.204 g),급약제량분별위26,13 g/kg,1차/d.③사군자탕조관복사군자탕(유당삼、백술、복령、구감초조성)26 g/kg,1차/d.각조련속용약16 d,급약체적균위0.5 mL/지,급약결속후,측정각조소서비、신조직DNA、RNA화단백질함량;병측정각조소서조모전급용약결속후체질량화비、신질량/체질량비치적변화.주요관찰지표:①각조동물조모전급용약16 d후체질량적변화.②각조동물비、신조직질량적변화.③용약16 d후각조동물비、신조직DNA、RNA화단백질함량적비교.결과:180지소서전부진입결과분석,무탈실.①실험전각조소서체질량17.4-21 g차이불현저(P=0.993;실험결속후비허모형조소서체질량현저저우정상대조조(Q=22.84,P＜0.01);강기건력구복액(26,13 g/kg)화사군자탕관복16 d후,소서체질량현저고우비허모형조(Q=8.66～10.24,P＜0.01).②비허모형조소서비、신조직질량/체질량비치균비정상대조조현저하강(Q=4.02～12.93,P＜0.01),강기건력구복액26、13 g/kg조화사군자탕조비、신조직질량교비허모형조증가(Q=3.21～9.69,P＜0.05～0.01),강기건력구복액13 g/kg조비조직비치화신조직비치균대우비허모형조(Q=4.07,5.92,P＜0.05,0.01).③비허모형조소서비조직DNA、RNA、단백질함량화신조직RNA、단백질함량저우정상대조조(Q=7.15～19.2,P＜0.01),신조직DNA고우정상대조조(Q=4.19,P＜0.05).강기건력구복액26 g/kg조화사군자탕조비조직DNA、RNA、단백질함량화신조직RNA、단백질함량고우비허모형조(Q=2.91～14.12,P＜0.05～0.01).결론:강기건력구복액능촉진핵산화단백질합성;비허증적발생여핵산급단백질합성감소가능유관.
BACKGROUND: Qiangji jianli liquid plays a key role in prevention and cure of myasthenia gravis; however, whether changes of nucleic acid and protein are related to its mechanism or not should be studied further.OBJECTIVE: To observe the effect of qiangji jianli liquid on synthesis of nucleic acid and protein in mice with experimental spleen deficiency syndrome, and investigate the effect on myasthenia gravis and the molecular biological basis.DESIGN: Randomized controlled animal study.SETTING: Testing Center and Basic Medical College of Guangzhou University of Traditional Chinese Medicine.MATERIALS: Healthy male NIH mice, aged 4 weeks, of clean grade, weighing 17-21 g, were provided by Medical Experimental Animal Center of Guangdong Province. Qiangji jianli liquid (Guangdong Dongfang Shencao Pharmaceutical Factory); serpate solution (Guangdong Bangmin Pharmaceutical Factory); [5-methyl-3H] TdR, [5-3H] uridine and L-[4,5-3H]leucine (Atom High-nuclear Technology Application Limited Company).METHODS: The experiment was carried out in the Laboratory of Nuclear Medicine of Guangzhou University of Traditional Chinese Medicine from June to November 2005. A total of 180 healthy male NIH mice were randomly divided into normal control group, model group, 26 g/kg qiangji jianli liquid group, 13 g/kg qiangjijianli liquid group and sijunzi decoction group with 36 in each group. Except normal control group, serpate was used to establish animal models of spleen deficiency syndrome. 0.2 mg/(kg ·d) serpate was intraperitoneally injected into mice. ① 0.1 mL/(mouse·d) saline was intraperitoneally injected into mice in normal control group. ② 26 g/kg and 13 g/kg were perfused into mice in 26 g/kg and 13 g/kg qiangji jianli liquid groups, respectively, once a day. Qiangji jianli liquid consisted of beiqi, dangshen, shengma,baizhu, gaicao, etc., with 1.204 g raw drugs a milliliter. ③ 26 g/kg sijunzi decoction, which consisted of dangshen,baizhu, fuling, jiugancao, etc., was perfused into mice with the dosage of 0.5 mL/mouse in si junzi decoction group once a day. After 16 successive days, contents of DNA, RNA and protein were measured in spleen and kidney tissue; meanwhile, body mass, ratio between spleen mass and body mass, and ratio between kidney mass and body mass were also measured before modeling and after administration.MAIN OUTCOME MEASURES: ① Changes of body mass before modeling and at 16 days after administration; ② changes of mass of spleen and kidney tissues; ③ Comparisons of DNA, RNA and protein in spleen and kidney tissues at 16 days after administration.RESULTS: All 180 mice were involved in the final analysis without any loss. ① There was no significant difference of body mass (17.4-21 g) among groups before experiment (P =0.993); however, after experiment, body mass in model group was lower than that in normal control group (Q =22.84, P ＜ 0.01); 16 days after administration, body mass was higher in qiangji jianli liquid groups (26 g/kg, 13 g/kg) and sijunzi decoction group than that in model group (Q =8.66-10.24, P ＜ 0.01). ② Values of spleen mass/body mass and kidney mass/body mass were decreased in model group as compared with those in normal control group (Q =4.02-12.93, P ＜ 0.01); masses of spleen and kidney tissues were increased in qiangji jianli liquid groups (26 g/kg, 13 g/kg) and sijunzi decoction group as compared with those in model group (Q =3.21-9.69, P ＜ 0.05-0.01); ratios in 13 g/kg qiangji jianli liquid group were higher than those in model group (Q =4.07, 5.92; P ＜ 0.05, 0.01). ③ Contents of DNA, RNA and protein in spleen tissue and contents of RNA and protein in kidney tissue were lower in model group than those in normal control group (Q =7.15-19.2, P＜ 0.01); however, content of DNA in kidney tissue was higher in model group than that in normal control group (Q =4.19, P ＜ 0.05). Contents of DNA, RNA and protein in spleen tissue and contents of RNA and protein in kidney tissue were higher in 26 g/kg qiangji jianli liquid group and sijunzi decoction group than those in model group (Q =2.91-14.12, P ＜ 0.05-0.01 ).CONCLUSION: Qiangji jianli liquid can accelerate synthesis of nucleic acid and protein; additionally, onset of spleen deficiency syndrome may be related to decreasing synthesis of nucleic acid and protein.
